< Back to previous page
Researcher
Karen Vanhoorelbeke
- Disciplines:Biochemistry and metabolism, Cardiac and vascular medicine, Medical biochemistry and metabolism
Affiliations
- Chemistry, Kulak Kortrijk Campus (Department)
Responsible
From1 Oct 2018 → Today - Chemistry, Kulak Kortrijk Campus (Department)
Member
From1 Jan 2009 → Today - Faculty of Medicine (Faculty)
Member
From1 Oct 2004 → 30 Sep 2006 - Faculty of Science, Kulak Kortrijk Campus (Faculty)
Member
From1 Oct 2000 → 31 Dec 2008
Projects
1 - 10 of 58
- B-specific: B-cell related gene and protein markers with prognostic and therapeutic value for CVDFrom1 Oct 2023 → TodayFunding: Horizon Europe - European Innovation Council (EIC)
- A novel targeted therapy to treat bleeding in patients with a left ventricular assist device.From1 May 2023 → TodayFunding: IOF - mandates
- Universal Chimeric Antigen Receptor (UniCAR) T-cell therapy: an innovative treatment for autoimmune diseaseFrom5 Apr 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Universal chimeric antigen receptor (uniCAR)-T cell therapy to treat autoimmune diseases: immune mediated thrombotic thrombocytopenic purpura as a model system.From1 Mar 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Flow cytometer for the Interdisciplinary Research Facility Life Sciences at Campus Kulak KortrijkFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Allosteric ADAMTS13 activation: elucidating long-range structural crosstalk bringing the enzyme in a preactivated stateFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- An integrated approach to restore tolerance in autoimmune diseaseFrom1 Oct 2022 → TodayFunding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
- Next-generation DNA vectors to improve efficacy, precision and accessibility of antibody gene transferFrom15 Mar 2022 → 14 Mar 2024Funding: BOF - various
- Innovative approaches to tackle autoimmune diseases: immune-mediated thrombotic thrombocytopenic purpura as a disease modelFrom1 Jul 2021 → 30 Jun 2023Funding: BOF - various
- A novel biomarker to improve the quality of life of immune mediatied thrombotic thrombocytopenic purpura patients.From1 Jun 2021 → 31 May 2023Funding: Foreign foundations, funds with scientific view
Publications
1 - 10 of 210
- Peak ADAMTS13 activity to assess ADAMTS13 conformation and risk of relapse in immune-mediated Thrombotic Thrombocytopenic Purpura.(2024)
Authors: Karen Vanhoorelbeke
Pages: blood.2023 - Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura(2024)
Authors: Claudia Tersteeg, Karen Vanhoorelbeke
Pages: 493 - 502 - Management and follow-up of pregnancy-onset thrombotic thrombocytopenic purpura: the French experience(2024)
Authors: Karen Vanhoorelbeke
Pages: 183 - 193 - Hemophagocytic lymphohistiocytosis is associated with deficiency and closed conformation of ADAMTS-13(2024)
Authors: Karen Vanhoorelbeke
- Impact of N-glycan mediated shielding of ADAMTS-13 on the binding of pathogenic antibodies in immune thrombotic thrombocytopenic purpura(2023)
Authors: Karen Vanhoorelbeke
Pages: 3402 - 3413 - FLUIDOT: A case study on drug tolerance screening and antibody mining, one cell at a time(2023)
Authors: Karen Ven, Jolien Breukers, Iene Rutten, Maya Imbrechts, Sam Noppen, Dominique Schols, Paul De Munter, Hendrik Jan Thibaut, Karen Vanhoorelbeke, Dragana Spasic, et al.
- ADAMTS13 and Non-ADAMTS13 Biomarkers in Immune-Mediated Thrombotic Thrombocytopenic Purpura(2023)
Authors: Quintijn Bonnez, Karen Vanhoorelbeke
- Measuring ADAMTS-13 activity to diagnose thrombotic thrombocytopenic purpura: a novel, fast fiber-optic surface plasmon resonance immunoassay(2023)
Authors: Quintijn Bonnez, Peter Verhamme, Claudia Tersteeg, Simon De Meyer, Jeroen Lammertyn, Karen Vanhoorelbeke
- Small-Molecule Cyclophilin Inhibitors Potently Reduce Platelet Procoagulant Activity(2023)
Authors: Simon De Meyer, Karen Vanhoorelbeke, Claudia Tersteeg
- Comparison of ADAMTS13 activity testing platforms for diagnosis and monitoring of thrombotic thrombocytopenic purpura(2023)
Authors: Karen Vanhoorelbeke
Pages: 26 - 26
Patents
1 - 9 of 9
- Haemorrhagic disorder due to ventricular assist device (Inventor)
- Humanised adamts13 binding antibodies (Inventor)
- Screening and sorting of single cells (Inventor)
- Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device (Inventor)
- Humanised adamts13 binding antibodies (Inventor)
- Screening and sorting of single cells (Inventor)
- Haemorrhagic disorder due to ventricular assist device (Inventor)
- Humanised adamts13 binding antibodies (Inventor)
- Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device (Inventor)